Vanguard Group Inc Sesen Bio, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.49 - $0.61 $2,076 - $2,584	4,237 Added 0.04%	10,854,300 $6.62 Million
Q3 2022 Nov 14, 2022	BUY	$0.0 - $0.93 $0 - $100,151	107,690 Added 1.0%	10,850,063 $4.61 Million
Q2 2022 Aug 12, 2022	SELL	$0.38 - $0.89 $741,913 - $1.74 Million	-1,952,403 Reduced 15.38%	10,742,373 $8.71 Million
Q1 2022 May 13, 2022	BUY	$0.58 - $0.86 $190,251 - $282,097	328,020 Added 2.65%	12,694,776 $7.65 Million
Q4 2021 Feb 14, 2022	BUY	$0.73 - $1.28 $1.58 Million - $2.77 Million	2,163,226 Added 21.2%	12,366,756 $10.1 Million
Q3 2021 Nov 12, 2021	BUY	$0.77 - $4.91 $1.31 Million - $8.34 Million	1,699,548 Added 19.99%	10,203,530 $8.09 Million
Q2 2021 Aug 13, 2021	BUY	$2.18 - $4.66 $18.5 Million - $39.6 Million	8,503,982 New	8,503,982 $39.3 Million

Ticker SESN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,702,000
Market Cap $127M
Description
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.